Bace1 Levels Are Increased in Plasma Of Alzheimer’S Disease Patients Compared with Matched Cognitively Healthy Controls

References

• Selkoe DJ . Amyloid beta-protein precursor: new clues to the genesis of Alzheimer’s disease . Curr. Opin. Neurobiol.4 ( 5 ), 708 – 716 ( 1994 ).
   PubMedGoogle Scholar
• Hardy J , SelkoeDJ . The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics . Science297 ( 5580 ), 353 – 356 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Mattson MP . Pathways towards and away from Alzheimer’s disease . Nature430 ( 7000 ), 631 – 639 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Schroeder A , FahrenholzF , SchmittU . Effect of a dominant-negative form of ADAM10 in a mouse model of Alzheimer’s disease . J. Alzheimers Dis.16 ( 2 ), 309 – 314 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Kandalepas PC , VassarR . The normal and pathologic roles of the Alzheimer’s beta-secretase, BACE1 . Curr. Alzheimer Res.11 ( 5 ), 441 – 449 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Fukumoto H , CheungBS , HymanBT , IrizarryMC . Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease . Arch. Neurol.59 ( 9 ), 1381 – 1389 ( 2002 ).
   PubMedGoogle Scholar
• Nitrini R , CaramelliP , HerreraEJret al. Incidence of dementia in a community-dwelling Brazilian population . Alzheimer Dis. Assoc. Disord.18 ( 4 ), 241 – 246 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Borghi R , PatriarcaS , TraversoNet al. The increased activity of BACE1 correlates with oxidative stress in Alzheimer’s disease . Neurobiol. Aging28 ( 7 ), 1009 – 1014 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Song WJ , SonMY , LeeHW , SeoH , KimJH , ChungSH . Enhancement of BACE1 activity by p25/Cdk5-mediated phosphorylation in Alzheimer’s disease . PLoS ONE10 ( 8 ), e0136950 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Grimmer T , AlexopoulosP , TsolakidouAet al. Cerebrospinal fluid BACE1 activity and brain amyloid load in Alzheimer’s disease . ScientificWorldJournal2012 , 712048 ( 2012 ).
   PubMedGoogle Scholar
• Ewers M , ChengX , ZhongZet al. Increased CSF–BACE1 activity associated with decreased hippocampus volume in Alzheimer’s disease . J. Alzheimers Dis.25 ( 2 ), 373 – 381 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Hampel H , ShenY . Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer’s disease . Scand. J. Clin. Lab. Invest.69 ( 1 ), 8 – 12 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Stockley JH , O’NeillC . The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer’s disease brain . Biochem. Soc. Trans.35 ( Pt 3 ), 574 – 576 ( 2007 ).
   PubMedGoogle Scholar
• Johnston JA , LiuWW , ToddSAet al. Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer’s disease . Biochem. Soc. Trans.33 ( Pt 5 ), 1096 – 1100 ( 2005 ).
   PubMedGoogle Scholar
• Cole SL , VassarR . The Alzheimer’s disease beta-secretase enzyme, BACE1 . Mol. Neurodegener.2 ( 1 ), 22 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Hussain I , HawkinsJ , ShikotraA , RiddellDR , FallerA , DingwallC . Characterization of the ectodomain shedding of the β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) . J. Biol. Chem.278 ( 38 ), 36264 – 36268 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Murayama KS , KametaniF , ArakiW . Extracellular release of BACE1 holoproteins from human neuronal cells . Biochem. Biophys. Res. Commun.338 ( 2 ), 800 – 807 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Wu G , SankaranarayananS , WongJet al. Characterization of plasma beta-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer’s disease . J. Neurosci. Res.90 ( 12 ), 2247 – 2258 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• McKhann GM , KnopmanDS , ChertkowHet al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease . Alzheimers Dement.7 ( 3 ), 263 – 269 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Snyder HM , CarrilloMC , GrodsteinFet al. Developing novel blood-based biomarkers for Alzheimer’s disease . Alzheimers Dement.10 ( 1 ), 109 – 114 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Chiam JT , DobsonRJ , KiddleSJ , SattleckerM . Are blood-based protein biomarkers for Alzheimer’s disease also involved in other brain disorders? A systematic review . J. Alzheimers Dis.43 ( 1 ), 303 – 314 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Humpel C . Identifying and validating biomarkers for Alzheimer’s disease . Trends Biotechnol.29 ( 1 ), 26 – 32 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Morris JC . The Clinical Dementia Rating (CDR): current version and scoring rules . Neurology43 , 2412 – 2414 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Brucki SM , NitriniR , CaramelliP , BertolucciPH , OkamotoIH . [Suggestions for utilization of the mini-mental state examination in Brazil] . Arq. Neuropsiquiatr.61 ( 3B ), 777 – 781 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• DeLong ER , DeLongDM , Clarke-PearsonDL . Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach . Biometrics44 ( 3 ), 837 – 845 ( 1988 ).
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Association National Plan Milestone Workgroup , FargoKN , AisenPet al.2014 report on the milestones for the US national plan to address Alzheimer’s disease . Alzheimers Dement.10 ( Suppl. 5 ), S430 – S452 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Yang LB , LindholmK , YanRet al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease . Nat. Med.9 ( 1 ), 3 – 4 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Holsinger RM , McLeanCA , BeyreutherK , MastersCL , EvinG . Increased expression of the amyloid precursor beta-secretase in Alzheimer’s disease . Ann. Neurol.51 ( 6 ), 783 – 786 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Coulson DT , BeyerN , QuinnJGet al. BACE1 mRNA expression in Alzheimer’s disease postmortem brain tissue . J. Alzheimers Dis.22 ( 4 ), 1111 – 1122 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Gatta LB , AlbertiniA , RavidR , FinazziD . Levels of beta-secretase BACE and alpha-secretase ADAM10 mRNAs in Alzheimer hippocampus . Neuroreport13 ( 16 ), 2031 – 2033 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Holsinger RM , LeeJS , BoydA , MastersCL , CollinsSJ . CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias . Neurology67 ( 4 ), 710 – 712 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Verheijen JH , HuismanLG , Van LentNet al. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay . Clin. Chem.52 ( 6 ), 1168 – 1174 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Zhong Z , EwersM , TeipelSet al. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment . Arch. Gen. Psychiatry64 ( 6 ), 718 – 726 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Mulder SD , Van Der FlierWM , VerheijenJHet al. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology . J. Alzheimers Dis.20 ( 1 ), 253 – 260 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Ewers M , ZhongZ , BurgerKet al. Increased CSF–BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer’s disease . Brain131 ( Pt 5 ), 1252 – 1258 ( 2008 ).
   PubMedGoogle Scholar
• Zetterberg H , AndreassonU , HanssonOet al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease . Arch. Neurol.65 ( 8 ), 1102 – 1107 ( 2008 ).
   PubMedGoogle Scholar
• Barao S , ZhouL , AdamczukKet al. BACE1 levels correlate with phospho-tau levels in human cerebrospinal fluid . Curr. Alzheimer Res.10 ( 7 ), 671 – 678 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Wu G , SankaranarayananS , TugushevaKet al. Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer’s subjects . Clin. Biochem.41 ( 12 ), 986 – 996 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Rosen C , AndreassonU , MattssonNet al. Cerebrospinal fluid profiles of amyloid beta-related biomarkers in Alzheimer’s disease . Neuromolecular Med.14 ( 1 ), 65 – 73 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Savage MJ , HolderDJ , WuG , KaplowJ , SiuciakJA , PotterWZ . Soluble BACE-1 activity and sAβPPβ concentrations in Alzheimer’s disease and age-matched healthy control cerebrospinal fluid from the Alzheimer’s disease neuroimaging initiative-1 baseline cohort . J. Alzheimers Dis.46 ( 2 ), 431 – 440 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Perneczky R , AlexopoulosP , Alzheimer’s Disease Euroimaging I . Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer’s disease . Alzheimers Dement.10 ( Suppl. 5 ), S425.e421 – S429.e421 ( 2014 ).
   Web of Science ®Google Scholar
• Li L , LuoJ , ChenDet al. BACE1 in the retina: a sensitive biomarker for monitoring early pathological changes in Alzheimer’s disease . Neural Regen. Res.11 ( 3 ), 447 – 453 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Ehehalt R , MichelB , De Pietri TonelliD , ZacchettiD , SimonsK , KellerP . Splice variants of the beta-site APP-cleaving enzyme BACE1 in human brain and pancreas . Biochem. Biophys. Res. Commun.293 ( 1 ), 30 – 37 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Johnston JA , LiuWW , CoulsonDTet al. Platelet beta-secretase activity is increased in Alzheimer’s disease . Neurobiol. Aging29 ( 5 ), 661 – 668 ( 2008 ).
   PubMed Web of Science ®Google Scholar